Treatment with GLP-1 RA was associated with a more significant benefit on composite cardiovascular outcomes (HR: 0.77; 95% CI: 0.69-0.87), myocardial infarction (HR: 0.82; 95% CI: 0.69-0.97), stroke (HR: 0.83; 95% CI: 0.74-0.93), cardiovascular mortality (HR: 0.76; 95% CI: 0.68-0.85) and all-cause mortality (HR: 0.65; 95% CI: 0.48-0.90). The gene discussed is GLP1R; the disease is Stroke.